Sugi Predict

Sugi Predict / Compounds / SCHEMBL1672256

SCHEMBL1672256

SCHEMBL1672256

Cc1ccc2c(c1C(=O)O)Cc1ccccc1O2

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAOA P21397 1/20 0.47
▸ MAOB P27338 1/20 0.47
▸ ACSL1 P33121 1/20 0.40
▸ ALOX5 P09917 2/20 0.37
▸ GSR P00390 1/20 0.36
▸ MAPKAPK2 P49137 1/20 0.36
▸ MEN1 O00255 2/20 0.34
▸ KMT2A Q03164 2/20 0.34
▸ RAB9A P51151 1/20 0.34
▸ KDM4E B2RXH2 2/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ GAA P10253 1/20 0.34
▸ HPGD P15428 1/20 0.34
▸ MAPK1 P28482 1/20 0.34
▸ NOTUM Q6P988 1/20 0.34
▸ HSD17B10 Q99714 1/20 0.34
▸ POLB P06746 1/20 0.34
▸ THRB P10828 1/20 0.34
▸ PKM P14618 1/20 0.34
▸ RECQL P46063 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28399575 0.87 MAOA (0.46) MAOAMAOBACSL1MAPKAPK2MEN1
SCHEMBL150427 0.85 MAOA (0.44) MAOAMAOBACSL1MAPKAPK2MEN1
SCHEMBL673811 0.85 MAOA (0.44) MAOAMAOBACSL1MAPKAPK2MEN1
Potassium Ion SCHEMBL3888005 0.85 MAOA (0.44) MAOAMAOBACSL1MAPKAPK2MEN1
SCHEMBL3890326 0.85 MAOA (0.44) MAOAMAOBACSL1MAPKAPK2MEN1
SCHEMBL673852 0.85 MAOA (0.44) MAOAMAOBACSL1MAPKAPK2MEN1
SCHEMBL672719 0.85 MAOA (0.44) MAOAMAOBACSL1MAPKAPK2MEN1
SCHEMBL11826523 0.85 MAOA (0.44) MAOAMAOBACSL1MAPKAPK2MEN1
SCHEMBL11512376 0.85 MAOA (0.44) MAOAMAOBACSL1MAPKAPK2MEN1
SCHEMBL11823426 0.85 MAOA (0.44) MAOAMAOBACSL1MAPKAPK2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-6009680-A — — None — — JP disclosed
CN-111892592-B JAK kinase inhibitors and uses thereof 江苏柯菲平医药股份有限公司 2023-09-19 — — CN disclosed
US-20220274983-A1 JAK KINASE INHIBITOR AND USE THEREOF JIANGSU CAREPHAR PHARMACEUTICAL CO., LTD. (CN) 2022-09-01 — — US disclosed
EP-4011880-A1 JAK KINASE INHIBITOR AND USE THEREOF Jiangsu Carephar Pharmaceutical Co., Ltd (CN) 2022-06-15 — — EP disclosed
CN-109374778-B Method for determining organic impurities in 2-mercaptobenzimidazole 长沙理工大学 2021-08-10 — — CN disclosed
EP-2716702-B1 METHOD FOR PRODUCING RUBBER COMPOSITION BRIDGESTONE CORP (JP) 2020-11-04 — — EP disclosed
EP-3077455-B1 PROCESS FOR PREPARING BLENDS OF CIS-1,4-POLYBUTADIENE AND SYNDIOTACTIC 1,2-POLYBUTADIENE BRIDGESTONE CORP (JP) 2020-08-12 — — EP disclosed
WO-2020081891-A1 PHOTOCURABLE RESIN COMPOSITION, PHOTOCURABLE RESIN ARTICLE, AND METHODS OF FABRICATING THE ARTICLE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2020-04-23 — — WO disclosed
EP-3511374-A1 PRODUCTION METHOD OF A RUBBER COMPOSITION Bridgestone Corporation (JP) 2019-07-17 — — EP disclosed
EP-3502176-A1 PRODUCTION METHOD OF A RUBBER COMPOSITION Bridgestone Corporation (JP) 2019-06-26 — — EP disclosed
WO-2002066525-A1 CHROMIUM-BASED CATALYST COMPOSITION BRIDGESTONE CORPORATION (JP) 2002-08-29 — — WO disclosed
WO-2002066523-A1 MANUFACTURE OF CONJUGATED DIENE POLYMERS USING AN IRON-BASED CATALYST COMPOSITION BRIDGESTONE CORPORATION (JP) 2002-08-29 — — WO disclosed
US-20020115558-A1 CHROMIUM-BASED CATALYST COMPOSITION FOR PRODUCING CONJUGATED DIENE POLYMERS BRIDGESTONE CORP. 2002-08-22 — — US disclosed
WO-2001079470-A2 USE OF A Mo-BASED CATALYST COMPOSITION TO CONTROL THE CHARACTERISTICS OF CONJUGATED DIENE POLYMERS BRIDGESTONE CORPORATION (JP) 2001-10-25 — — WO disclosed
WO-2001079308-A2 CR-BASED CATALYST COMPOSITION FOR THE MANUFACTURE OF CONJUGATED DIENE RUBBER BRIDGESTONE CORPORATION (JP) 2001-10-25 — — WO disclosed
WO-2001079309-A2 USE OF A Cr- OR Mo-BASED CATALYST SYSTEM TO PRODUCE BLENDS OF SYNDIOTACTIC 1,2-POLYBUTADIENE AND RUBBERY ELASTOMERS BRIDGESTONE CORPORATION (JP) 2001-10-25 — — WO disclosed
WO-2001062820-A1 PARTIALLY CONJUGATED POLY(ARYLENEVINYLENE)S ISIS INNOVATION LIMITED (GB) 2001-08-30 — — WO disclosed
JP-H069680-A 2'-FLUORO-2',3'-DIDEOXYPYRIMIDINE NUCLEOSIDE USA GOVERNMENT 1994-01-18 — — JP disclosed
US-4155761-A TELLURIUM COORDINATION COMPOUND AND REDUCING AGENT EASTMAN KODAK COMPANY (US) 1979-05-22 — — US disclosed
US-4155760-A NONSILVER PHOTOGRAPHY, TELLURIUM COORDINATION COMPOUND EASTMAN KODAK COMPANY (US) 1979-05-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220274983-A1 JAK KINASE INHIBITOR AND USE THEREOF JAK1, JAK2, JAK3 MAOA 3611/4885MAOB 3479/4885ACSL1 3734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.